THT140 not checked

Tethra Biosciences Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
1 active
1 in total · 1 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“THT140 is a highly selective, orally- and intravenously- available, ATP-competitive inhibitor of PLK1.”In the company’s words, NCT05358379 on ClinicalTrials.gov
Tested for
Solid Tumor, Adult Lymphoma
Main trialPhase 1/2
“This is a 2-part, phase 1/2, open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, pharmacogenomics, and efficacy of THT40 administered orally daily. This study consists of Phase 1 and Phase 2 components in subjects with advanced solid tumors and lymphoma with a focus on tumors with ARID1A and similar mutations who have progressed despite having received standard therapy or for whom no standard therapy exists.”In the company’s words, NCT05358379 on ClinicalTrials.gov
Other names
Plogosertib

Other drugs for Solid Tumor, Adult Lymphoma

All 309 drugs for Solid Tumor, Adult Lymphoma

Coming up1

Changes2

Last 90 days

Trials1

TrialPhaseCompletesWhat it tests
Phase 1/2Recruiting Nov 2028 A Study to Investigate THT140, in Subjects With Advanced Solid Tumors and Lymphoma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026

Follow THT140

Following is part of Solo: you see every change to THT140 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in